A novel augmentation strategy for treating resistant major depression.

Shelton, R C; Tollefson, G D; Tohen, M; Stahl, S; Gannon, K S; Jacobs, T G; Buras, W R; Bymaster, F P; Zhang, W; Spencer, K A; Feldman, P D; Meltzer, H Y

Shelton, R C; Tollefson, G D; Tohen, M; Stahl, S; Gannon, K S; Jacobs, T G; Buras, W R; Bymaster, F P; Zhang, W; Spencer, K A; Feldman, P D; Meltzer, H Y.

Affiliation

Shelton RC; Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN 37212, USA. richard.shelton@mcmail.vanderbilt.edu

Am J Psychiatry ; 158(1): 131-4, 2001 Jan.

Article in En | MEDLINE | ID: mdl-11136647

Subject(s)

Depressive Disorder/drug therapy; Fluoxetine/therapeutic use; Pirenzepine/analogs & derivatives; Pirenzepine/therapeutic use; Selective Serotonin Reuptake Inhibitors/therapeutic use; Ambulatory Care; Basal Ganglia Diseases/chemically induced; Basal Ganglia Diseases/epidemiology; Benzodiazepines; Depressive Disorder/psychology; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fluoxetine/administration & dosage; Fluoxetine/adverse effects; Humans; Olanzapine; Pirenzepine/administration & dosage; Pirenzepine/adverse effects; Selective Serotonin Reuptake Inhibitors/administration & dosage; Selective Serotonin Reuptake Inhibitors/adverse effects; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pirenzepine / Fluoxetine / Selective Serotonin Reuptake Inhibitors / Depressive Disorder Type of study: Clinical_trials Limits: Humans Language: En Journal: Am J Psychiatry Year: 2001 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links